Integra LifeSciences

Integra LifeSciences is a global leader in medical technology, dedicated to limiting uncertainty for surgeons so they can concentrate on providing the best patient care. Founded in 1989 with the acquisition of an engineered collagen technology platform, the company has become a pioneer in the field of regenerative medicine. This foundational technology was designed to repair and regenerate tissue, and it has since been expanded to address a wide range of clinical needs. The company's initial breakthrough came with the development of Integra® Dermal Regeneration Template, the first commercially reproducible skin tissue, which revolutionized the treatment of severe burns and other complex skin wounds. This innovation established Integra's reputation as a trailblazer in creating solutions that enable the body to regenerate damaged or diseased tissue.

Over the years, Integra has significantly broadened its portfolio through strategic acquisitions and robust internal product development. Today, the company offers a comprehensive range of products and solutions across two primary business segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS division is a leader in neurosurgery, providing a wide array of devices, instruments, and systems for neuro-critical care, dural access and repair, and cerebral spinal fluid management. The Tissue Technologies segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair, offering advanced regenerative technologies for soft tissue repair, and the treatment of acute and chronic wounds and burns. With a global presence in over 130 countries and manufacturing and research facilities across the Americas, Europe, and Asia-Pacific, Integra LifeSciences continues to innovate treatment pathways, advance patient outcomes, and set new standards of care in the medical technology industry.